Harnett PR - Search Results

1

LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.

Cowin PA, George J, Fereday S, Loehrer E, Van Loo P, Cullinane C, Etemadmoghadam D, Ftouni S, Galletta L, Anglesio MS, Hendley J, Bowes L, Sheppard KE, Christie EL, Pearson RB, Harnett PR, Heinzelmann-Schwarz V, Friedlander M, McNally O, Quinn M, Campbell P, deFazio A, Bowtell DD; Australian Ovarian Cancer Study. Cowin PA, et al. Among authors: harnett pr. Cancer Res. 2012 Aug 15;72(16):4060-73. doi: 10.1158/0008-5472.CAN-12-0203. Cancer Res. 2012. PMID: 22896685

2

Demonstration of somatic rearrangements and genomic heterogeneity in human ovarian cancer by DNA fingerprinting.

Boltz EM, Harnett P, Leary J, Houghton R, Kefford RF, Friedlander ML. Boltz EM, et al. Br J Cancer. 1990 Jul;62(1):23-7. doi: 10.1038/bjc.1990.222. Br J Cancer. 1990. PMID: 2390478 Free PMC article.

3

Persisting elevation of alpha-fetoprotein after chemotherapy for germ cell tumour--not always due to viable malignancy?

Shannon JA, Donnellan MJ, Friedlander ML, Harnett PR. Shannon JA, et al. Among authors: harnett pr. Eur J Cancer. 1995 Sep;31A(10):1722. doi: 10.1016/0959-8049(95)00303-z. Eur J Cancer. 1995. PMID: 7488439 No abstract available.

4

Mechanisms determining sensitivity to cisplatin in three mutant Chinese hamster ovary cell lines.

Segelov E, Mann G, deFazio A, Harnett PR. Segelov E, et al. Among authors: harnett pr. Mutat Res. 1998 Jun;407(3):243-52. doi: 10.1016/s0921-8777(98)00006-8. Mutat Res. 1998. PMID: 9653450

5

Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line--a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia.

Guminski AD, Harnett PR, deFazio A. Guminski AD, et al. Among authors: harnett pr. Cancer Chemother Pharmacol. 2001 Sep;48(3):229-34. doi: 10.1007/s002800100279. Cancer Chemother Pharmacol. 2001. PMID: 11592345

6

Scientists and clinicians test their metal-back to the future with platinum compounds.

Guminski AD, Harnett PR, deFazio A. Guminski AD, et al. Among authors: harnett pr. Lancet Oncol. 2002 May;3(5):312-8. doi: 10.1016/s1470-2045(02)00733-7. Lancet Oncol. 2002. PMID: 12067809 Review.

7

Incidence of microsatellite instability in synchronous tumors of the ovary and endometrium.

Shannon C, Kirk J, Barnetson R, Evans J, Schnitzler M, Quinn M, Hacker N, Crandon A, Harnett P. Shannon C, et al. Clin Cancer Res. 2003 Apr;9(4):1387-92. Clin Cancer Res. 2003. PMID: 12684409

8

Expression of progesterone receptor A and B isoforms in low-grade endometrial stromal sarcoma.

Balleine RL, Earls PJ, Webster LR, Mote PA, deFazio A, Harnett PR, Clarke CL. Balleine RL, et al. Among authors: harnett pr. Int J Gynecol Pathol. 2004 Apr;23(2):138-44. doi: 10.1097/00004347-200404000-00008. Int J Gynecol Pathol. 2004. PMID: 15084842

9

A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer.

Rischin D, Phillips KA, Friedlander M, Harnett P, Quinn M, Richardson G, Martin A. Rischin D, et al. Gynecol Oncol. 2004 May;93(2):417-21. doi: 10.1016/j.ygyno.2004.01.037. Gynecol Oncol. 2004. PMID: 15099955 Clinical Trial.

10

Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer.

Byrne JA, Balleine RL, Schoenberg Fejzo M, Mercieca J, Chiew YE, Livnat Y, St Heaps L, Peters GB, Byth K, Karlan BY, Slamon DJ, Harnett P, Defazio A. Byrne JA, et al. Int J Cancer. 2005 Dec 20;117(6):1049-54. doi: 10.1002/ijc.21250. Int J Cancer. 2005. PMID: 15986428

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

142 results

Search Page